share_log

国联证券4月22日发布研报称，给予仙乐健康（300791.SZ）买入评级，目标价格为44.18元。评级理由主要包括：1）营收及利润实现高增，中美欧三基地走向成熟；2）降本增效成果显著，盈利水平有望稳步提升。（每日经济新闻）

Guolian Securities released a research report on April 22 stating that it gave Xianle Health (300791.SZ) a purchase rating, and the target price was 44.18 yuan. The main reasons for the rating include: 1) the high increase in revenue and profit, and the m

Zhitong Finance ·  Apr 22 16:01
Guolian Securities released a research report on April 22 stating that it gave Xianle Health (300791.SZ) a purchase rating, and the target price was 44.18 yuan. The main reasons for the rating include: 1) the high increase in revenue and profit, and the maturity of the three bases in China, the US, and Europe; 2) the results of cost reduction and efficiency are remarkable, and profit levels are expected to rise steadily. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment